SeQure DX On-Target and Off-Target Editing Assessment Services SeQure DX Comprehensive Suite of On-target and Off-target Assessment Assays SeQure DX GUIDE-seq – Nomination Assay

GUIDE-seq™

Nomination assay

SeQure DX's GUIDE-seq is a cell-based, orthogonal nomination assay that validates and reinforces ONE-seq™ findings to support regulatory requirements. GUIDE-seq utilizes co-transfection of a DNA tag alongside your gene editing tool of interest to profile potential off-target effects in your chosen cell type.

Request a consultation

Download product sheet

GUIDE-seq overview

GUIDE-seq

Orthogonal approach to supplement ONE-seq off-target nomination. Unbiased, cell-based, off-target editing assay provides a complementary approach to supplement your off-target risk assessment efforts. Available either as a fully turnkey assay service provided by SeQure DX or as a licensable offering.

Nomination

Comprehensive off-target assessment

Highly sensitive
Universal for all editors
Population-scale variant assessment

Off-target assessment
IND filings
Guide RNA selection

Multiple orthogonal methods
Variant effect prediction
GLP

Featured resources

Poster

ONE-seq for Variant-Aware Therapeutic Guide Selection

Shown here in a line graph are cumulative counts of candidate off-target loci based on their ONE-seq scores. All loci with assigned ONE-seq scores are represented here. As ONE-seq score increases, number of off-target loci decreases dramatically, indicating that majority of sites do not show clear evidence for cleavage in the ONE-seq assay.

Example Customer Report

ONE-seq Nomination Assay Example Report

A table for guides that then lists off-target score (by MIT and CFD), Activity (CRISPRater), number of loci (L. Distance, and Risk Profiler number.

Poster

Guide Profiler: A Genetic Variant-Aware Computational Tool for Improved Guide RNA Selection for CRISPR-Based Therapeutic Applications

View all resources

Related nomination assays

ONE-seq

Gold standard population-scale, variant-aware, off-target detection. Candidate off-target enumeration, enrichment and biochemical in vitro cutting combined with deep sequencing enables high-sensitivity detection of low-frequency off-target events.

DEUX-seq

Orthogonal approach to supplement ONE-seq off-target nomination. Unbiased, biochemical, off-target editing assay provides a complementary approach to supplement your off-target risk assessment efforts.